Patent intelligence · CN
CN 120418289
Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors
Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors
Patent details — CN 120418289
- Jurisdiction
- CN
- Status
- granted
- Grant date
- Aug 1, 2025
- Expiration
- Jul 27, 2045
- Applicant
- ASTELLAS PHARMA EUROPE B V
- CPC classes
- A61P 35/ 00 A I, A61P/3500
Quick answer
CN 120418289 (Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors) is held by ASTELLAS PHARMA EUROPE B V. Status: granted. Granted Aug 1, 2025. Expires Jul 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS PHARMA EUROPE B V
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P 35/ 00 A I, A61P/3500
More from ASTELLAS PHARMA EUROPE B V
Related pharmaceutical patents in our USPTO index.
-
KR 20240032847
CLDN18.2 및 CD3에 결합하는 이중특이 결합제
granted -
CN 105120840
Composition of tiacumicin compounds
granted -
EP 1549658
VERBINDUNGEN AUF GLUKOSEBASIS MIT AFFINITÜT FÜR P-SELEKTIN
expired -
EP 1527086
VERBINDUNGEN DIE P-SELECTIN BINDEN
expired -
EP 1423413
SELEKTIV P-SELECTIN BINDENDE PEPTIDISCHE VERBINDUNGEN
expired -
EP 1392755
ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE
expired -
IS 5505
Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju
expired
Frequently asked questions
What is US patent 120418289?
CN 120418289 (Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors) is held by ASTELLAS PHARMA EUROPE B V. Status: granted. Granted Aug 1, 2025. Expires Jul 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CN 120418289?
ASTELLAS PHARMA EUROPE B V is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does CN 120418289 expire?
Our index shows an expiration date of Jul 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.